Cost-Effectiveness Analysis of Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer in Portugal
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.206
https://www.valueinhealthjournal.com/article/S1098-3015(17)30540-5/fulltext
Title :
Cost-Effectiveness Analysis of Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30540-5&doi=10.1016/j.jval.2017.08.206
First page :
A434
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
186